These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 11143573)

  • 21. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women.
    da Costa LS; de Oliveira MA; Rubim VS; Wajngarten M; Aldrighi JM; Rosano GM; Neto CD; Gebara OC
    Am J Cardiol; 2004 Dec; 94(11):1453-6. PubMed ID: 15566926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of estrogen deficiency symptoms in women surviving breast cancer.
    Climacteric; 1998 Jun; 1(2):148-58. PubMed ID: 11907918
    [No Abstract]   [Full Text] [Related]  

  • 23. Hormone therapy and raloxifene reduce the coagulation inhibitor potential.
    Andresen MS; Eilertsen AL; Abildgaard U; Sandset PM
    Blood Coagul Fibrinolysis; 2007 Jul; 18(5):455-60. PubMed ID: 17581320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T; Mizunuma H
    Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raloxifene therapy in postmenopausal women is associated with a significant reduction in the concentration of serum vascular endothelial growth factor.
    Lam PM; Yim SF; Briton-Jones C; Chung TK; Haines C
    Fertil Steril; 2004 Feb; 81(2):393-7. PubMed ID: 14967379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [SERM--selective estrogen receptor modulators].
    Kønig KB; Eiken PA; Schwarz P
    Ugeskr Laeger; 2001 Apr; 163(15):2129-33. PubMed ID: 11332210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies.
    Rogers A; Clowes JA; Pereda CA; Eastell R
    Bone; 2007 Jan; 40(1):105-10. PubMed ID: 16934544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raloxifene: another selective estrogen modulator.
    Kellen JA
    In Vivo; 2001; 15(6):459-60. PubMed ID: 11887329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half].
    MMW Fortschr Med; 2003 May; 145(22):57. PubMed ID: 12866287
    [No Abstract]   [Full Text] [Related]  

  • 31. Raloxifene for hormone replacement therapy (HRT).
    Adams D
    N Z Med J; 2005 May; 118(1214):U1451. PubMed ID: 15886741
    [No Abstract]   [Full Text] [Related]  

  • 32. Raloxifene: bone and cardiovascular effects.
    Francucci CM; Romagni P; Boscaro M
    J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemoprevention of breast cancer: recommendations and rationale.
    Am Fam Physician; 2003 Mar; 67(6):1309-14. PubMed ID: 12674459
    [No Abstract]   [Full Text] [Related]  

  • 34. [Role of estrogen and selective estrogen receptor modulators in anti-aging].
    Ohta H
    Clin Calcium; 2008 Jul; 18(7):986-94. PubMed ID: 18591752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hormone replacement therapy and cardiovascular prevention. Where are we now?].
    Lerman J; Siseles N
    Medicina (B Aires); 2008; 68(3):251-7. PubMed ID: 18689159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevention of breast cancer--what are the latest developments?].
    Nahum R; Kaplan B; Ben-Rafael Z
    Harefuah; 2001 Jan; 140(1):32-4. PubMed ID: 11242896
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of Raloxifen in treatment of fibromyalgia in menopausal women.
    Sadreddini S; Molaeefard M; Noshad H; Ardalan M; Asadi A
    Eur J Intern Med; 2008 Jul; 19(5):350-5. PubMed ID: 18549938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.
    Valiati B; Capp E; Edelweiss MI; de Freitas FM; Wender MC
    Maturitas; 2009 Jan; 62(1):81-4. PubMed ID: 19097715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gonadotropin-releasing hormone agonist with or without raloxifene: effects on cognition, mood, and quality of life.
    Palomba S; Orio F; Russo T; Falbo A; Amati A; Zullo F
    Fertil Steril; 2004 Aug; 82(2):480-2. PubMed ID: 15302308
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.